

# KARO PHARMA

## NOTICE OF EXTRAORDINARY GENERAL MEETING IN KARO PHARMA AKTIEBOLAG

*At the request of Karo Intressenter AB ("Karo Intressenter"), which, as of the date of this notice, is registered shareholder of approximately 19.3 percent of the total number of outstanding shares and votes in Karo Pharma Aktiebolag, reg. no. 556309-3359 (the "Company" or "Karo Pharma"), the shareholders of Karo Pharma are given notice of the extraordinary general meeting to be held at 15:00 CET on Thursday 14 February 2019, at Näringslivets Hus, Storgatan 19 in Stockholm.*

### Right to participate

Shareholders who wish to participate in the extraordinary general meeting must *both* be registered in the share register maintained by Euroclear Sweden AB on Friday 8 February 2019, *and also* notify the Company of their intention to attend the meeting no later than Friday 8 February 2019.

Shareholders with nominee-registered shares must temporarily register their shares in their own name with Euroclear Sweden to attend the meeting. Such registration must be completed by Friday 8 February 2019 and should be requested well in advance of this date to the nominee of the shares.

### Notification to attend

Notification to attend the meeting shall be submitted in writing to the address Karo Pharma AB, att: Mats-Olof Wallin, Nybrokajen 7, SE-111 48 Stockholm, Sweden or by email to mats-olof.wallin@karopharma.se. Name, personal identification number or corporate identity number, phone number daytime and number of shares held shall be included in the notification to attend. Where applicable, the number of advisors (maximum two) shall be stated. If a shareholder intends to be represented by proxy, power of attorney and other authorization documents should be included in the notification. The original authorization documents must be able to be presented at the meeting. Proxy forms are available from the Company and at the Company's website and will be sent to shareholders who provide their postal address.

### Proposal for agenda

1. Opening
2. Election of chairman of the meeting
3. Preparation and approval of the voting list
4. Approval of the agenda
5. Election of person to confirm the minutes
6. Determination as to whether the meeting has been duly convened
7. Determination of the number of members of the board of directors
8. Election of new members of the board of directors
9. Determination of remuneration to the board of directors
10. Closing

## **Proposals**

### **Proposal regarding number of members of the board of directors, the composition of the board of directors and remuneration to the board of directors (item 7-9)**

Karo Intressenter has informed that they will provide the board of directors of Karo Pharma with its proposals prior to the meeting. Karo Pharma will announce the proposals from Karo Intressenter once received.

## **Information to shareholders**

Shareholders have right to ask questions regarding the items on the agenda at the meeting.

## **Number of shares and votes in the Company**

At the time of issue of this notice, the total number of shares and votes in the Company is 164,332,782, of which the Company owns 2,464,990 shares.

## **Processing of personal data**

For information about the processing of your personal data, please refer to the privacy notice available at Euroclear's website: <https://www.euroclear.com/dam/ESw/Legal/Privacy-notice-bolagsstammengelska.pdf>.

---

Stockholm in January 2019

**Karo Pharma Aktiebolag**

*The board of directors*